Metraipolis › archive › dc_cf119db81141
Anti-ROR1 scFv-EndoG as a Novel Anti-Cancer Therapeutic Drug — Europe PMC PMID:29373898
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/29373898
- DOI
- 10.22034/apjcp.2018.19.1.97
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T09:18:56.687Z
- SHA-256 of the archived text
9d7c04efb0ba1f6be5526fd5da0c9c8b9d83f82ec2665e643073281153a128ce- Stable URL of this page
https://metraipolis.com/documento/dc_cf119db81141
How to cite
Anti-ROR1 scFv-EndoG as a Novel Anti-Cancer Therapeutic Drug — Europe PMC PMID:29373898 — Europe PMC (en), https://europepmc.org/article/MED/29373898 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cf119db81141 (Metraipolis archive dc_cf119db81141, sha256 9d7c04efb0ba1f6be5526fd5da0c9c8b9d83f82ec2665e643073281153a128ce)
BibTeX
@misc{dccf119db81141,
title = {Anti-ROR1 scFv-EndoG as a Novel Anti-Cancer Therapeutic Drug — Europe PMC PMID:29373898},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/29373898},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cf119db81141; sha256 9d7c04efb0ba1f6be5526fd5da0c9c8b9d83f82ec2665e643073281153a128ce},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/29373898. Agents can read the archived copy with the MCP tool read_document.